(1R)-1-[3-[(2-Benzthiazolyl)-methoxy]phenyl]-2-(N-methyl-N-diethylcarbamoyl)amino ethanol | 110193-16-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: (1R)-1-[3-[(2-Benzthiazolyl)-methoxy]phenyl]-2-(N-methyl-N-diethylcarbamoyl)amino ethanol
• 英文别名: 1-[(2R)-2-[3-(1,3-benzothiazol-2-ylmethoxy)phenyl]-2-hydroxyethyl]-3,3-diethyl-1-methylurea
• CAS: 110193-16-3
• 化学式: C₂₂H₂₇N₃O₃S
• 分子量: 413.541
• InChiKey: YAXDDYBKRXOVIR-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  94.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  盐酸去氧肾上腺素 在 caesium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 49.0h， 生成 (1R)-1-[3-[(2-Benzthiazolyl)-methoxy]phenyl]-2-(N-methyl-N-diethylcarbamoyl)amino ethanol
  参考文献：
  名称：

  Phenylephrine derivatives as leukotriene D4 antagonists

  摘要：

  Two series of phenylephrine derivatives were prepared and tested as inhibitors of leukotriene D4 (LTD4) induced and ovalbumin-induced bronchospasm in the guinea pig. The most potent compound of the urea series, (R)-N,N-diethyl-N-[2-hydroxy-2-[3-(2-quinolinylmethoxy)phenyl]ethyl]-N- methylurea (3, Wy-47,120), was orally active with ED50's of 56 mg/kg vs. LTD4 and 55 mg/kg vs. ovalbumin. When tested as an antagonist of LTD4-induced contraction of isolated guinea pig tracheal strips, 3 was a competitive inhibitor with a p kappa B value of 5.22. In the second series, (R)-3-methyl-5-[3-(2-quinolinylmethoxy)phenyl]-2-oxazolidinone (26, Wy-47,674) had oral ED50's of 36 mg/kg against LTD4 and 95 mg/kg against ovalbumin. Compound 26 selectively antagonized contractile responses of guinea pig trachea evoked by LTD4 (p kappa B = 6.09). In the cat coronary artery, 3 dilated the preparation and blocked the coronary constrictor effect of LTD4. Compound 3 (0.13 mg/kg, iv) also preserved myocardial integrity in rats 48 h after coronary artery ligation. When tested in the rat alcohol-induced gastric lesion model, 3 and 26 manifested a dose-dependent mucosal protection against ethanol.

  DOI：

  10.1021/jm00394a026

文献信息

• Quinoline compounds
  申请人：American Home Products Corporation

  公开号：US04876346A1

  公开（公告）日：1989-10-24

  There are disclosed compounds of the formula ##STR1## wherein X is N or CR.sup.1 Y is O, S, NR.sup.1, CHR.sup.1 or C(R.sup.1).sub.2 when n=O, or N or CR.sup.1 when n=1; p is 0-3; R.sup.1 is hydrogen or lower alkyl; R.sup.2 is H, ##STR2## --SO.sub.2 R.sup.3 or --SO.sub.2 N(R.sup.3).sub.2, lower alkyl, lower alkenyl, lower alkynyl or lower alkyl carbonyl prolinate; R.sup.3 is H, lower alkyl or perfluoro lower alkyl; R.sup.4 is lower alkyl, phenyl, pyridyl or thienyl; R.sup.5 is hydrogen, lower alkyl, phenyl or pyridyl; A is O or NR.sup.1 ; B is OR.sup.1 or N(R.sup.5).sub.2 ; m is 0-2; and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like.

  公开了公式##STR1##中的化合物，其中X为N或CR.sup.1，Y为O、S、NR.sup.1、CHR.sup.1或C(R.sup.1).sub.2（当n=O时），或N或CR.sup.1（当n=1时）；p为0-3；R.sup.1为氢或低碳基；R.sup.2为H、##STR2## --SO.sub.2 R.sup.3或--SO.sub.2 N(R.sup.3).sub.2、低碳基、低烯基、低炔基或低碳基羰基脯氨酸；R.sup.3为H、低碳基或全氟低碳基；R.sup.4为低碳基、苯基、吡啶基或噻吩基；R.sup.5为氢、低碳基、苯基或吡啶基；A为O或NR.sup.1；B为OR.sup.1或N(R.sup.5).sub.2；m为0-2；以及其药学上可接受的盐，并且它们在治疗白三烯介导的鼻-支气管阻塞性气道疾病方面的用途，如过敏性鼻炎、过敏性支气管哮喘等。
• MUSSER, JOHN H.;KREFT, ANTHONY F.;BENDER, REINHOLD H. W.
  作者：MUSSER, JOHN H.、KREFT, ANTHONY F.、BENDER, REINHOLD H. W.

  DOI：——

  日期：——
• US4876346A
  申请人：——

  公开号：US4876346A

  公开（公告）日：1989-10-24
• Phenylephrine derivatives as leukotriene D4 antagonists
  作者：John H. Musser、Dennis M. Kubrak、Reinhold H. W. Bender、Anthony F. Kreft、Susan T. Nielsen、Allan M. Lefer、Joseph Chang、Alan J. Lewis、James M. Hand

  DOI：10.1021/jm00394a026

  日期：1987.11

  Two series of phenylephrine derivatives were prepared and tested as inhibitors of leukotriene D4 (LTD4) induced and ovalbumin-induced bronchospasm in the guinea pig. The most potent compound of the urea series, (R)-N,N-diethyl-N-[2-hydroxy-2-[3-(2-quinolinylmethoxy)phenyl]ethyl]-N- methylurea (3, Wy-47,120), was orally active with ED50's of 56 mg/kg vs. LTD4 and 55 mg/kg vs. ovalbumin. When tested as an antagonist of LTD4-induced contraction of isolated guinea pig tracheal strips, 3 was a competitive inhibitor with a p kappa B value of 5.22. In the second series, (R)-3-methyl-5-[3-(2-quinolinylmethoxy)phenyl]-2-oxazolidinone (26, Wy-47,674) had oral ED50's of 36 mg/kg against LTD4 and 95 mg/kg against ovalbumin. Compound 26 selectively antagonized contractile responses of guinea pig trachea evoked by LTD4 (p kappa B = 6.09). In the cat coronary artery, 3 dilated the preparation and blocked the coronary constrictor effect of LTD4. Compound 3 (0.13 mg/kg, iv) also preserved myocardial integrity in rats 48 h after coronary artery ligation. When tested in the rat alcohol-induced gastric lesion model, 3 and 26 manifested a dose-dependent mucosal protection against ethanol.